Go Pro
OTCMKTS:MDNAF

Medicenna Therapeutics Q3 2026 Earnings Report

$0.31 0.00 (0.00%)
As of 09/18/2026 03:54 PM Eastern

Medicenna Therapeutics EPS Results

Actual EPS
-$0.05
Consensus EPS
-$0.04
Beat/Miss
Missed by -$0.01
One Year Ago EPS
N/A

Medicenna Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Medicenna Therapeutics Announcement Details

Quarter
Q3 2026
Time
After Market Closes
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Medicenna Therapeutics Earnings Headlines

Trump's New Dollar
Porter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. dollar reset - and most Americans don't know it's happening. The last time America underwent a monetary shift like this, under Nixon in the 1970s, it minted an average of 1,300 new millionaires a day for over half a century. Stansberry has released a new documentary naming the assets he believes are positioned to surge as a result.tc pixel
Medicenna Therapeutics Corp. GAAP EPS of -C$0.22
See More Medicenna Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Medicenna Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Medicenna Therapeutics and other key companies, straight to your email.

About Medicenna Therapeutics

Medicenna Therapeutics (OTCMKTS:MDNAF) is a Canadian clinical-stage biotechnology company focused on developing immunotherapies for cancer. The company uses its proprietary Superkine platform to engineer cytokine-based medicines designed to stimulate or direct immune responses against tumors while potentially reducing some of the limitations associated with naturally occurring cytokines.

Its lead program, MDNA11, is an engineered interleukin-2 (IL-2) super-agonist intended to activate cancer-fighting immune cells and is being evaluated in clinical studies for advanced solid tumors. Medicenna has also developed MDNA55, an IL-4–targeted fusion protein designed to deliver a cell-killing payload to tumors that express the interleukin-4 receptor, including recurrent glioblastoma. The company’s development activities have included clinical research in North America and collaborations with academic and clinical institutions.

Medicenna was founded in Canada and is headquartered in Toronto, Ontario. The company is led by Fahar Merchant, who serves as president and chief executive officer and is one of its founders. Medicenna’s shares trade in the United States under the symbol MDNAF.

View Medicenna Therapeutics Profile